The role of Interleukin-33 in patients with mild cognitive impairment and Alzheimer’s disease

Chih-Sung Liang (lcsyfw@gmail.com)
Tri-Service General Hospital Beitou Branch  https://orcid.org/0000-0003-1138-5586

Kuan-Pin Su
China Medical University

Chia-Lin Tsai
Tri-Service General Hospital

Jiunn-Tay Lee
Tri-Service General Hospital

Che-Sheng Chu
Kaohsiung Veterans General Hospital

Ta-Chuan Yeh
Tri-Service General Hospital

Ming-Wei Su
Institute of Biomedical Science, Academia Sinica

Guan-Yu Lin
Tri-Service General Hospital

Yu-Kai Lin
Tri-Service General Hospital

Hsuan-Te Chu
Tri-Service General Hospital Beitou Branch

Chia-Kuang Tsai
Tri-Service General Hospital

Fu-Chi Yang
Tri-Service General Hospital

Research article

Keywords: cytokine; interleukin-33; Alzheimer’s disease; mild cognitive disorder; cognitive decline

DOI: https://doi.org/10.21203/rs.3.rs-20645/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: The neuroprotective role of Interleukin (IL)-33 is supported in numerous pre-clinical studies but remains mostly uninvestigated in clinical studies of Alzheimer’s disease (AD). We aimed to examine the association between human blood levels of IL-33 and cognitive preservation in amnestic mild cognitive impairment (aMCI) and AD.

Methods: A total of 100 participants (26 controls, 35 aMCI patients, and 39 AD patients) were completed twice Mini Mental State Examination (MMSE) over a 1-year interval. At the second MMSE, the 100 participants examined the plasma levels of IL-33, IL-β, IL-1 receptor agonist (IL-1RA), beta amyloid (Aβ), and tau and apolipoprotein E (ApoE) genotyping, and Hopkins Verbal Learning Test, Trail Making Test, forward and backward digit span, and Clinical Dementia Rating were performed as well.

Results: IL-33 expression showed a positive trend among controls (1/26 = 3.8%), aMCI (9/35 = 25.7%), and AD (17/39 = 43.6%) (trend analysis: P < 0.001). The patients expressing IL-33 preserved their cognitive function compared with IL-33 non-expressing patients (1-year ΔMMSE: 0.16 ± 1.6 vs -1.5 ± 2.6; P = 0.006). The cognitive preservation was not associated with the lower levels of Aβ, tau, and ApoE ε4, while higher levels of ApoE ε4 and phosphorylated tau were indeed associated with cognitive decline. The aMCI patients with AD conversion during study period had higher proportion of IL-33(-) than non-AD converters (0.9% vs 53.3%, P = 0.04).

Conclusions: IL-33 or its associated signaling pathways may represent a new treatment paradigm for aMCI and AD.

Background

The main pathophysiology of Alzheimer’s disease (AD) involve the accumulation of insoluble forms of amyloid-beta (Aβ) peptide into plaques and the aggregation of the microtubule protein tau into neurofibrillary tangles [1–4]. In addition to amyloid and tau hypotheses, substantial evidence suggests that innate immune system-mediated actions drive and exacerbate AD pathogenesis [5–7]. Importantly, in the preclinical stages of AD, neuroinflammation triggers a vicious cycle of microglial activation, pro-inflammatory factors release, and neuronal damage. Exploration of innate immune-mediated mechanisms and the use of immunomodulation as disease-modification strategy have been promising in the preclinical research of AD [8]. Animal studies have showed that targeting the innate immune molecules or their respective signaling pathways may substantially ameliorate the AD-related pathology [8, 9].

Interleukin (IL)-33 is a member of the IL-1 family and broadly expressed in stromal and barrier tissue, including oligodendrocytes and astrocytes in the central nervous system (CNS) [10, 11]. Although IL-33 is originally thought to be a cellular alarmin released from nuclear stores after tissue damage, new in vivo data found astrocyte-derived IL-33 is the key molecule promoting synapse refinement by microglia during CNS development [12]. Increasing evidence also indicates the critical role of IL-33 in shaping type 1, type
2, and regulatory immune responses [10]. Previous studies have showed that another IL-1 family, IL-1β, led to robust reduction of amyloid plaque pathology in AD mouse models [13, 14]. Supporting IL-33 as a therapeutic target in AD comes from animal and human cellular and genetic studies [15–17]. An animal study showed that peripheral IL-33 administration reduced soluble Aβ levels and amyloid plaque deposition, and reversed synaptic plasticity impairment and cognitive decline in AD mouse models [15]. Another animal study reported that IL-33 deficiency caused tau abnormality, neurodegeneration, and AD-like symptoms in aged mice [16]. Consistent with these findings, a human genetic study showed that IL-33 expression is reduced in the brains of AD [18]. Another human study reported that compared with the mild cognitive impairment (MCI) patients with subsequent AD conversion, the MCI patients without AD conversion had higher levels of IL-33+ cells that were also positively correlated with hippocampus volumes [17]. These findings suggested the potential therapeutic role of IL-33 in AD.

To date, no human study has examined the association between IL-33 and cognitive preservation in MCI and AD. Here, we showed that < 50% of MCI and AD patients had peripheral IL-33 expression, and these IL-33 expressing patients preserved their cognitive function over 1-year period compared with those patients without IL-33 expression. The cognitive preservation was not associated with the levels of Aβ and tau protein, the risk factors of AD. In contrast, higher apolipoprotein E (ApoE) ε4 expression and higher levels of phosphorylated tau 181 (p-Tau) was associated with rapid cognitive decline. Moreover, IL-33 non-expression was associated with AD conversion in the MCI patients. Collectively, this is the first human study supporting the association between the peripheral IL-33 expression and cognitive preservation in MCI and AD.

Methods

Subjects and study design

The protocol was approved by the Institutional Review Board for the Protection of Human Subjects at the Tri-Service General Hospital (TSGHIRB 1-107-05-111). A total of 109 participants aged between 64 and 88 years were recruited between Jan 2015 and Dec 2018 at the memory clinic at the Tri-Service General Hospital of the National Defense Medical Center, Taiwan. Individuals were eligible if they had negative findings on physical and neurological examinations, laboratory test (creatinine, fasting blood sugar, free-thyroxine 4, high-sensitivity thyroid stimulating hormone, vitamin B12, folic acid, serologic test for syphilis, and routine blood tests), and neuroimaging examinations (brain computed tomography or magnetic resonance imaging).

Participants underwent baseline Mini Mental Status Examination (MMSE) on recruitment. After 1-year follow-up, the following cognitive tests were performed, including MMSE, Clinical Dementia Rating (CDR), short-form Geriatric Depression Scale (GDS-S), Hopkins Verbal Learning Test (HVLT), forward and backward digit span, Trail Making Test, Part A (TMTA), and Hachinski Ischemia Scale (HIS).
Individuals were excluded if they had: (a) a history of major or uncontrolled medical condition, such as heart failure, sepsis, liver cirrhosis, renal failure, chronic obstructive pulmonary disease, and poorly controlled diabetes (Hemoglobin A1c > 8.5), myocardial infarction, or malignancy; (b) substance abuse; (c) a history of major neurological disorders, such as stroke or Parkinson's disease; and (d) GDS-S > 9 or modified Rankin Scale scores > 3; and (e) a history of major psychiatric condition that can impair cognition, such as major depressive disorder, bipolar disorder, or schizophrenia.

Participants were allocated to control group, MCI due to AD (aMCI) group, and AD group based on the results of HVLT, MMSE, CDR, and HVLT and the recommendations from the National Institute on Aging-Alzheimer’s Association (NIA-AA) workgroups on diagnostic guidelines for AD and aMCI [19, 20].

Normal controls were required to satisfy: (a) no active neurological or psychiatric disorders; (b) no psychotropic drugs; (c) MMSE > 26 (middle school), MMSE > 22 (primary school), MMSE > 19 (illiteracy); and (d) CDR score = 0.

In addition to NIA-AA criteria [19], aMCI was required to satisfy the following criteria: (a) CDR = 0.5; (b) MMSE > 26 (middle school), MMSE > 22 (primary school), MMSE > 19 (illiteracy); (c) HIS ≤ 3; and (d) HVLT ≤ 22 [21].

In addition to NIA-AA criteria [20], AD was required to satisfy the following criteria: (a) CDR ≥ 0.5; (b) MMSE ≤ 26 (middle school), MMSE ≤ 22 (primary school), MMSE ≤ 19 (illiteracy); (c) HIS ≤ 3; and (d) HVLT ≤ 19 [21].

**Preparation of plasma samples**

Fasting blood was drawn using 9 mL K3-EDTA tubes (455036, Greiner Bio-one GmbH, Kremsmünster, Austria), which were gently inverted three times immediately following blood collection. Blood samples were then centrifuged at a relative centrifugal force (2300 g) for 10 min (4 °C) using a swing-out (bucket) rotor (5202R, Eppendorf, Hamburg, Germany). Each 0.4-mL plasma sample was transferred to a fresh 2.0-mL tube (CryzoTraq, Ziath, Cambridge, United Kingdom). All plasma samples were stored in 0.5 ml aliquots at −80 °C within 8 h of blood collection. For the measurements of the cytokine levels, the plasma sample were thawed on ice, and 50-µl aliquots were prepared and stored at −80 °C.

**Plasma levels of Aβ and tau protein**

Immunomagnetic reduction (IMR), an ultra-sensitive analytical assay method, can reliably assay ultra-low concentrations of human blood biomarkers, including Aβ1−40, Aβ1−42, total tau (t-Tau), and p-Tau181 [22]. For each plasma sample, the levels of Aβ1−40, Aβ1−42, t-Tau, and p-Tau181 were assayed using IMR kits (MF-AB0-0060, MF-AB2-0060, MF-TAU-0060, and MF-PT1-0060, MagQu Co., New Taipei City, Taiwan). For each assay, 40 µL (Aβ1−40, t-Tau, and p-Tau181) or 60 µL (Aβ1−42) of plasma was mixed with 80 or 60 µL of reagent, respectively. Each reported biomarker concentration represents the average of duplicated measurements. An IMR analyzer (XacPro-S, MagQu Co., New Taipei City, Taiwan) was used for all assays. The reliable IMR measurements ranged from 0.17 to 1000 pg/mL for Aβ1−40, 0.77 to
30,000 pg/mL for Aβ₁₋₄₂, 0.026 to 3000 pg/mL for t-Tau, and 0.0196 to 1000 pg/mL for p-Tau. The intra-assay or inter-assay coefficient of assay variation using IMR was within the range of 7–10% for high-concentration quality control samples of Aβ₁₋₄₀, Aβ₁₋₄₂, t-Tau, or p-Tau. For low-concentration quality control samples of Aβ₁₋₄₀, Aβ₁₋₄₂, t-Tau, or p-Tau using IMR, the intra-assay or inter-assay coefficient of assay variation was within the range of 10–15%. For each kind of biomarker, two batches of reagent were used. The quality of each batch of reagents was well controlled by monitoring particle size, particle concentration, and bioactivity. The variation in these reagent properties between batches is lower than 10%.

**Plasma levels of cytokines**

A multiplex bead array assay was used to examine plasma levels of cytokines. The detailed procedures for detection of soluble cytokines by multiplex bead array assays have been previously reported [23, 24]. Three cytokines (IL-1β, IL-1 receptor antagonist (RA), and IL-33) were determined by using a customized human cytokine magnetic bead panel (Bio-Rad; Yu-Shing Biotech., Ltd, Taipei, Taiwan) according to the manufacturer's instructions (Bio-Rad; Genmall Biotechnology Co., LTD., Taipei, Taiwan). The median fluorescence intensities were collected on Bio-Plex 200 instrument (Bio-Rad) using Bio-Plex Manager software version 6.0 (Bio-Rad). Study samples were tested in duplicate and the duplicate measurements were averaged for statistical analysis. Standard curves were created from duplicate values and all samples were analyzed as single determinations. All analyses were performed in one batch using kits from the same production lot.

**ApoE genotyping**

To efficiently obtain genetic information from samples collected from Taiwanese patients of Han Chinese ethnicity, the Taiwan Biobank (TWB) designed the TWB genotype array, based on the Affymetrix Axiom genotyping platform. The TWB genotype array enabled good-quality genotyping. Two single-nucleotide polymorphisms (SNPs, rs429358 and rs7412) defining Apo E isoforms were genotyped using the TWB array.

**Statistical analysis**

Categorical variables were analyzed using Pearson's chi-square test and continuous variables were analyzed using Student's t-test or Mann–Whitney test. Trend analysis was analyzed using Cochran-Armitage test. All tests were two-sided, and P < 0.05 was considered significant. Error bars represent mean ± standard deviation. All statistical analyses were performed using SPSS software version 25.0 (IBM SPSS, IBM Corp., Armonk, NY, USA) and GraphPad Prism software version 8.0 (GraphPad Software, San Diego, CA, USA).

**Results**

**The demographics and cognitive performance**
A total of 100 individuals fulfilled the study criteria and completed the second MMSE, of which 26 were healthy controls (HC), 35 were aMCI, and 39 were AD. We first examined the group-differences in demographics and cognitive performance. Table 1 shows the demographics of the three groups. The patient group (aMCI plus AD) were older (P < 0.001) and had higher education level (P = 0.02) than the control group. Their performance on all of the cognitive tests (all P < 0.001) were also poorer than healthy controls.
### Table 1
Clinical characteristics of participants

|                           | Controls (N = 26) | Patients (N = 74) | P     | Patient group |             |             | P     |
|---------------------------|-------------------|-------------------|-------|---------------|-------------|-------------|-------|
|                           |                   |                   |       | aMCI (N = 35) | AD (N = 39) |             |       |
| Female (%)                | 21 (80.8%)        | 52 (70.3%)        | 0.30  | 23 (65.7%)    | 29 (74.4%)  | 0.42        |       |
| Age (year)                | 68.7 ± 4.2        | 76.7 ± 8.5        | <0.001| 75.6 ± 8.4    | 77.7 ± 8.5  | 0.30        |       |
| Body mass index           | 23.7 ± 3.3        | 24.4 ± 3.4        | 0.38  | 24.5 ± 3.2    | 24.3 ± 3.7  | 0.82        |       |
| Education (year)          | 11.4 ± 4.2        | 8.8 ± 4.9         | 0.02  | 9.2 ± 5.1     | 8.4 ± 4.7   | 0.51        |       |
| First MMSE                | 28.4 ± 0.8        | 23.9 ± 5.8        | <0.001| 26.9 ± 2.3    | 21.2 ± 6.7  | <0.001      |       |
| Second MMSE               | 28.4 ± 1.5        | 22.9 ± 5.8        | <0.001| 26.5 ± 2.0    | 19.7 ± 6.2  | <0.001      |       |
| Hopkins Verbal Learning Test | 23.4 ± 3.7        | 15.0 ± 4.9        | <0.001| 16.7 ± 4.4    | 13.5 ± 4.9  | 0.005       |       |
| Forward digit span        | 11.7 ± 1.7        | 9.0 ± 2.6         | <0.001| 9.3 ± 2.5     | 8.6 ± 2.6   | 0.26        |       |
| Backward digit span       | 7.2 ± 2.7         | 3.8 ± 2.4         | <0.001| 4.7 ± 2.3     | 3.0 ± 2.1   | 0.001       |       |
| Trail Making Test Part A  | 56.7 ± 25.6       | 115.3 ± 86.5      | <0.001| 87.6 ± 67.7   | 140.2 ± 94.5| 0.007       |       |
| Clinical Dementia Rating  | 0.04 ± 0.14       | 1.05 ± 0.72       | <0.001| 0.50 ± 0.00   | 1.54 ± 0.68 | <0.001     |       |
| Apolipoprotein E ε2:ε3:ε4 | 7:12:7 (27%:46%:27%) | 9:50:15 (12%:68%:20%) | 0.109 | 2:28:5 (6%:80%:14%) | 7:22:10 (18%:56%:26%) | 0.084 |       |

Data are presented as mean ± standard deviation or frequency (percentage).

Abbreviation: aMCI, mild cognitive impairment due to Alzheimer’s disease; AD, Alzheimer’s disease; MMSE, Mini Mental State Examination.
We next examined the demographic and cognitive differences between aMCI and AD patients. Compared with aMCI patients, AD patients showed poorer performance on first (P < 0.001) and second MMSE (P < 0.001), HVLT (P = 0.005), backward digit span (P = 0.001), TMTA (P = 0.007), and CDR (P < 0.001). Both groups did not differ in female proportion, age, body mass index, and education levels.

The peripheral levels of IL-33 in HC, aMCI, and AD

We next sought to examine the peripheral levels of IL-33 among the three groups. The lowest limit of detection for IL-33 was 0.2 pg/ml. Among the 100 samples, the IL-33 levels were detectable only in 28 samples. We analyzed IL-33 data as a binary variable. IL-33(+) indicates detectable IL-33 levels and IL-33(-) undetectable. The proportion of IL-33(+) in each group are shown in Fig. 1. The three groups had significantly different proportion of IL-33(+) (P = 0.002), and HC, aMCI, and AD showed a positive linear trend (3.8%, 25.7%, 43.6%; P < 0.001).

The peripheral levels of Aβ1−42, Aβ1−40, t-Tau, p-Tau, IL-1β, and IL-1RA

To explore group-differences in AD-related biomarkers, we then examined the peripheral levels of Aβ1−42, Aβ1−40, t-Tau, and p-Tau in the three groups. Table 2 shows the results of these biomarkers. As expected, the patient group had higher levels of Aβ1−42 (17.3 ± 1.0 vs 16.9 ± 0.7, P = 0.038), t-Tau (26.6 ± 5.1 vs 23.8 ± 3.9, P = 0.014), and p-Tau (4.1 ± 0.9 vs 3.7 ± 0.7, P = 0.035) than the control group. The levels of these biomarkers were higher in AD than in aMCI patients, with no statistical significance.

Table 2
IMR data and cytokine levels

|                      | Patient group vs Control group | Patient group |
|----------------------|--------------------------------|---------------|
|                      | Controls (N = 26) | Patients (N = 74) | P | aMCI (N = 35) | AD (N = 39) | P |
| Aβ1−40               | 50.7 ± 4.9       | 52.1 ± 4.2       | 0.160 | 51.9 ± 4.8   | 52.3 ± 3.7   | 0.654 |
| Aβ1−42               | 16.9 ± 0.7       | 17.3 ± 1.0       | 0.038 | 17.2 ± 1.1   | 17.4 ± 0.9   | 0.455 |
| t-Tau                | 23.8 ± 3.9       | 26.6 ± 5.1       | 0.014 | 26.0 ± 5.1   | 27.1 ± 5.2   | 0.374 |
| p-Tau181             | 3.7 ± 0.7        | 4.1 ± 0.9        | 0.035 | 4.0 ± 0.9    | 4.2 ± 0.9    | 0.340 |
| IL-1β                | 0.07 ± 0.04      | 0.12 ± 0.11      | 0.039 | 0.12 ± 0.11  | 0.12 ± 0.12  | 0.765 |
| IL-1RA               | 63 ± 31          | 96 ± 79          | 0.045 | 108 ± 104    | 85 ± 45      | 0.289 |

Abbreviation: aMCI, mild cognitive impairment due to Alzheimer’s disease; AD, Alzheimer’s disease; IL, interleukin; IL-1RA, interleukin 1 receptor antagonist.
Table 2 also presents group-differences in cytokine data. The other two IL-1 family (IL-1β and IL-1RA) were 100% detectable in the control and the patient groups. The patient group had higher levels of IL-1β (0.12 ± 0.11 vs 0.07 ± 0.04, P = 0.039) and IL-1RA (96 ± 79 vs 63 ± 31, P = 0.045) compared with the control group. The comparisons between aMCI and AD in IL-1β and IL-1RA did not reach statistical significance.

**The association between IL-33 expression and cognitive preservation**

To determine whether IL-33 expression might be a protective factor for aMCI and AD patients, we examined the association between IL-33 expression and 1-year change in MMSE. The aMCI and AD patients were divided into two groups: IL-33(+) and IL-33(-). The IL-33(+) patients did not differ from the IL-33(-) patients in female proportion (76.9% vs 66.7%, P = 0.357), age (77.0 ± 8.6 vs 76.6 ± 8.5, P = 0.848), education levels (8.4 ± 5.1 vs 9.0 ± 4.8, P = 0.632), and BMI (24.0 ± 3.5 vs 24.6 ± 3.4, P = 0.455).

Figure 2 shows that the IL-33(+) patients significantly preserved their general cognitive function compared with the IL-33(-) patients (1-year ΔMMSE of IL-33(+) vs IL-33(-): 0.16 ± 1.6 vs -1.5 ± 2.6; P = 0.006).

We then examined whether the IL-33(+) patients had lower levels of Aβ or tau that may contribute to their cognitive preservation. The Fig. 3 shows that the IL-33(+) patients did not have lower levels of Aβ or tau. Instead, the IL-33(+) patients had higher levels of Aβ1−40 than the IL-33(-) patients (53.5 ± 4.3 vs 51.3 ± 4.1, P = 0.035). However, whey analyzing Aβ1−42/Aβ1−40 ratio, group difference did not reach significance (IL-33(+) vs IL-33(-): 0.33 ± 0.04 vs 0.34 ± 0.03, P = 0.130). We also examined whether the IL-33(+) patients had lower expression of ApoE ε4. The proportion of ApoE ε4 expression did not differ significantly between groups [IL-33(+) vs IL-33(-): 15.4% vs 22.9%, P = 0.442]]).

We next assessed the levels of IL-1β and IL-1RA between IL-33(+) and IL-33(-) patients. We found that the IL-33(+) patients had higher levels of IL-1β than IL-33(-) patients (0.15 ± 0.14 vs 0.10 ± 0.10, P = 0.011). The levels of IL-1RA was also higher in IL-33(+) patients than IL-33(-) patients but with no statistical significance (96.1 ± 40.2 vs 95.6 ± 94.0, P = 0.189).

**The association between cognitive preservation and Aβ, tau, and ApoE ε4**

Aβ, tau, and ApoE ε4 are well-known risk factors of AD, and thereby we sought to examine whether ApoE ε4 non-expression and lower levels of Aβ and tau might be associated with cognitive preservation. The patient group was divided into two categories—high and low—according to the calculated mean value of f Aβ1−42, Aβ1−40, t-Tau, and p-Tau. Figure 3 shows that ApoE ε4 non-expression and lower levels of Aβ1−42, Aβ1−40, t-Tau, and p-Tau were not associated with cognitive preservation. However, ApoE ε4 expression (P = 0.009) and higher levels of p-Tau (P = 0.038) were significantly associated with cognitive decline compared with ApoE ε4 non-expression and lower levels of p-Tau, respectively.
IL-33(-) between aMCI with AD conversion vs aMCI without AD conversion

Finally, we sought to test whether IL-33(-) patients may have higher risk of AD conversion. The aMCI patients without any decline between the first and second MMSE were defined as non-AD converter, while the AD patients with first MMSE > 27 (middle school), > 23 (primary school), > 20 (illiteracy) were defined as AD converters. For example, an AD patient with 9-year education level had first MMSE score of 27 and second MMSE score of 24 were allocated into AD converter. Thus, we identified 11 AD converters and 15 non-AD converters. We next examined the proportion of IL-33(-) between AD converters and non-AD converters. Our results showed that AD converters had higher proportion of IL-33(-) than non-AD converters (90.9% vs 53.3%, P = 0.04).

Discussion

The CNS has the highest levels of IL-33 expression in all human organs [10–12], and recent basic and preclinical studies have extend its physiological and pathophysiological role in CNS development [12, 16], recovery [11, 25, 26], and disease [10, 15, 18]. Here we further our understanding of the IL-33 in human AD research. The main findings of this study were that: (1) most of healthy controls did not have detectable levels of peripheral IL-33; (2) the IL-33 expression showed positive linear trend between healthy controls, aMCI, and AD; (3) the IL-33 expressing patients preserved their cognitive function over 1-year period; (4) the cognitive preservation was not associated with the levels of Aβ and tau and the expression of ApoE ε4; and (5) the aMCI patients with subsequent AD conversion had higher proportion of IL-33 non-expression.

In our study, the aMCI and AD patients had higher peripheral levels of Aβ1−42, t-Tau, and p-Tau than controls, indirectly reflecting their central neurodegenerative conditions. The aMCI and AD patients lacking IL-33 expression revealed significantly cognitive decline, while the patients with IL-33 expression preserved their cognitive function over 1-year period. This finding was consistent with the bidirectional relationship between IL-33 deficiency and neurodegeneration in several studies, including: (1) mice lacking IL-33 had persistent inflammation and severe neurodegeneration in retinal detachment [27]; (2) IL-33 deficiency mice failed to repair deoxyribonucleic acid damage of aged neuron, resulting in neurodegeneration and tau abnormality [16]; (3) mice lacking IL-33 were found to impaired recovery after CNS injury [11]; and (4) IL-33 treatment rescued contextual memory deficits in AD mouse models [15]. Collectively, our study provided the first human evidence that linking IL-33 to neurodegeneration in the aMCI and AD patients.

Comparisons between our study and the animal studies with manipulation of IL-33 revealed inconsistent findings. An animal study showed that peripheral administration of IL-33 could reduce soluble Aβ levels and reverse cognitive decline in AD mouse models [15]. Our aMCI and AD patients with IL-33 expression did not have lower levels of Aβ and Tau. In addition, the IL-33 expressing patients had higher levels of IL-1β, which has also been shown to reduce amyloid plaque pathology in AD mouse models [13, 14].
Importantly, our study design was observational in nature, and we did not observe the findings from the animal study showing that exogenous IL-33 administration rescued AD mice-related brain neuropathology [15]. However, we found a significant and positive association between IL-33 expression and cognitive preservation. Future longitudinal studies are needed to warrant the Aβ-IL-33 link in human studies.

Our followed-up data were coherent with a human study addressing the baseline differences between MCI with subsequent AD conversion and MCI without subsequent AD conversion [17]. Compared with AD converters, AD non-converters had increased baseline levels of IL-33+ cell that was also positively correlated with baseline bilateral hippocampus volumes [17]. These findings indirectly supported the association between IL-33 deficiency and neurodegeneration. Indeed, in our study, the AD converters had higher proportion of IL-33 non-expression than the AD non-converters.

Although our study found a positive linear trend of IL-33 expression among heathy controls (3.8%), aMCI (25.7%), and AD (43.6%), the longitudinal changes of IL-33 expression remains unclear in aMCI and AD. Several line of evidence suggests that AD-related neurodegeneration begins 20 years or more before the affected individual experiences noticeable symptoms [1]. The IL-33 non-expression in aMCI and AD may be a condition of deficiency (insufficient production) or a consequence of depletion (excessive consumption). A previous study found lower baseline levels of IL-33+ cell in MCI patients with AD conversion [17], which was consistent with our study showing a lower followed-up levels of peripheral IL-33 levels in aMCI patients with AD conversion. Another human genetic study reported lower levels of IL-33 expression in the brain of AD cases than controls [18]. Taken these findings together, insufficient production of IL-33, rather than IL-33 depletion, might be associated with the risk of AD conversion and rapid cognitive decline. However, future studies need to prospectively examine the levels of IL-33 in preclinical stage of aMCI and AD.

Our study has limitations. First, the bioactivity of IL-33 is limited in blood [28]. A study measured the serum levels of IL-33 in 30 healthy controls and found that all of the samples were undetectable (lowest limit of detection: 75 pg/ml). Therefore, future study addressing the role of IL-33 in AD can simultaneously measure IL-33 and its receptor ST2. Second, our sample size was small. Therefore, our findings need to be validated by future large-scale studies. Third, several biomarkers were only measured once. Future studies should assess the longitudinal changes of IL-33, Aβ, and tau in association with the cognitive decline. Finally, the correlation between the CSF levels of IL-33 and the peripheral levels of IL-33 remains to be determined.

**Conclusions**

This is an early foray into the association of IL-33 in human AD research, indicating an association between IL-33 expression and cognitive preservation in aMCI and AD patients. Unanswered key questions include the underlying mechanism of IL-33 deficiency in mediating cognition decline in aMCI and AD and
the trajectory of IL-33 expression from preclinical AD stage to full-blown AD. In conclusion, our findings suggest that IL-33 or its associated signaling pathways may represent a new treatment paradigm for AD.

**Abbreviations**

**AD:** Alzheimer’s disease  

**ApoE:** apolipoprotein E  

**Aβ:** amyloid-beta  

**CDR:** Clinical Dementia Rating  

**CNS:** central nervous system  

**GDS-S:** short-form Geriatric Depression Scale  

**HIS:** Hachinski Ischemia Scale  

**HVLT:** Hopkins Verbal Learning Test  

**IMR:** Immunomagnetic reduction  

**IL:** interleukin  

**MCI:** mild cognitive impairment  

**MMSE:** Mini Mental Status Examination  

**NIA-AA:** National Institute on Aging-Alzheimer’s Association  

**RA:** receptor antagonist  

**TMTA:** Trail Making Test, Part A  

**TWB:** Taiwan Biobank  

**aMCI:** MCI due to AD  

**a-Tau:** total tau  

**p-Tau:** phosphorylated tau 181  

**Declarations**

**Ethics approval and consent to participate**
The protocol was approved by the Institutional Review Board for the Protection of Human Subjects at the Tri-Service General Hospital (TSGHIRB 1-107-05-111). Written informed consent was obtained from all participants.

**Consent for publication**

All authors have approved of the manuscript and agree with its submission.

**Availability of data and materials**

The datasets during and/or analyzed during the current study available from the corresponding author on reasonable request.

**Competing interests**

The authors declare that they have no competing interests.

**Funding source**

This study was supported by grants from the Ministry of Science and Technology of Taiwan (MOST 106-2314-B-016-007-MY2, MOST 108-2314-B-016-023-), Tri-Service General Hospital (TSGH-C106-068, TSGH-C108-100, TSGH-C108-216), and Beitou Branch, Tri-Service General Hospital (TSGH-BT-108-01).

**Authors’ contributors**

Chih-Sung Liang managed the literature review, conducted statistical analyses, interpreted results, and wrote the first draft of the manuscript. Kuan-Pin Su designed the study, directed data collection, provided conceptualization and theory used to integrate the findings, and edited the manuscript. Chia-Lin Tsai played a major role in the acquisition of data and revised the manuscript for intellectual content. Jiunn-Tay Lee designed the study and provided conceptualization and theory used to integrate the findings, and edited the manuscript. Che-Sheng Chu interpreted the data and revised the manuscript for intellectual content. Ta-Chuan Yeh interpreted the data and revised the manuscript for intellectual content. Ming-Wei Su interpreted the data and revised the manuscript for intellectual content. Guan-Yu Lin interpreted the data and revised the manuscript for intellectual content. Yu-Kai Lin interpreted the results and provided feedback and comments on the various versions of the manuscript. Hsuan-Te Chu interpreted the data and revised the manuscript for intellectual content. Chia-Kuang Tsai interpreted the results and provided feedback and comments on the various versions of the manuscript. Fu-Chi Yang designed the study, directed data collection, provided overall scientific supervision, interpreted results, and edited the manuscript.

All authors read and approved the final manuscript.

**Acknowledgements**
We thank Shieh-Yueh Yang at MagQu Co., Ltd. and MagQu LLC for assistance with the assays for plasma biomarkers and Ruei-Yi Chao for performing neuropsychological assessments during the study period. The study was conducted using Taiwan Biobank resources.

References

1. Association. As: 2019 Alzheimer’s disease facts and figures. Alzheimers Dement 2019;15:321-387.
2. Lucey BP, Fagan AM, Holtzman DM, Morris JC, Bateman RJ: Diurnal oscillation of CSF Abeta and other AD biomarkers. Mol Neurodegener 2017;12:36.
3. Stancu IC, Vasconcelos B, Terwel D, Dewachter I: Models of beta-amyloid induced Tau-pathology: the long and "folded" road to understand the mechanism. Mol Neurodegener 2014;9:51.
4. DeTure MA, Dickson DW: The neuropathological diagnosis of Alzheimer's disease. Mol Neurodegener 2019;14:32.
5. Cao W, Zheng H: Peripheral immune system in aging and Alzheimer's disease. Mol Neurodegener 2018;13:51.
6. Cao J, Hou J, Ping J, Cai D: Advances in developing novel therapeutic strategies for Alzheimer's disease. Mol Neurodegener 2018;13:64.
7. Frank-Cannon TC, Alto LT, McAlpine FE, Tansey MG: Does neuroinflammation fan the flame in neurodegenerative diseases? Mol Neurodegener 2009;4:47.
8. Heppner FL, Ransohoff RM, Becher B: Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci 2015;16:358-372.
9. Rangaraju S, Dammer EB, Raza SA, Rathakrishnan P, Xiao H, Gao T, Duong DM, Pennington MW, Lah JJ, Seyfried NT et al: Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease. Mol Neurodegener 2018;13:24.
10. Liew FY, Girard JP, Turnquist HR: Interleukin-33 in health and disease. Nat Rev Immunol 2016;16:676-689.
11. Gadani SP, Walsh JT, Smirnov I, Zheng J, Kipnis J: The glia-derived alarmin IL-33 orchestrates the immune response and promotes recovery following CNS injury. Neuron 2015;85:703-709.
12. Vainchtein ID, Chin G, Cho FS, Kelley KW, Miller JG, Chien EC, Liddelow SA, Nguyen PT, Nakao-Inoue H, Dorman LC et al: Astrocyte-derived interleukin-33 promotes microglial synapse engulfment and neural circuit development. Science 2018;359:1269-1273.
13. Shaftel SS, Carlson TJ, Olschowka JA, Kyrkanides S, Matousek SB, O'Banion MK: Chronic interleukin-1beta expression in mouse brain leads to leukocyte infiltration and neutrophil-independent blood brain barrier permeability without overt neurodegeneration. J Neurosci 2007;27:9301-9309.
14. Ghosh S, Wu MD, Shaftel SS, Kyrkanides S, LaFerla FM, Olschowka JA, O'Banion MK: Sustained interleukin-1beta overexpression exacerbates tau pathology despite reduced amyloid burden in an Alzheimer's mouse model. J Neurosci 2013;33:5053-5064.
15. Fu AK, Hung KW, Yuen MY, Zhou X, Mak DS, Chan IC, Cheung TH, Zhang B, Fu WY, Liew FY et al: IL-33 ameliorates Alzheimer's disease-like pathology and cognitive decline. Proc Natl Acad Sci U S A 2016;113:E2705-2713.

16. Carlock C, Wu J, Shim J, Moreno-Gonzalez I, Pitcher MR, Hicks J, Suzuki A, Iwata J, Quevado J, Lou Y: Interleukin33 deficiency causes tau abnormality and neurodegeneration with Alzheimer-like symptoms in aged mice. Transl Psychiatry 2017;7:e1191.

17. La Rosa F, Saresella M, Baglio F, Piancone F, Marventano I, Calabrese E, Nemni R, Ripamonti E, Cabinio M, Clerici M: Immune and Imaging Correlates of Mild Cognitive Impairment Conversion to Alzheimer's Disease. Sci Rep 2017;7:16760.

18. Chapuis J, Hot D, Hansmannel F, Kerdraon O, Ferreira S, Hubans C, Maurage CA, Huot L, Bensemain F, Laumet G et al: Transcriptomic and genetic studies identify IL-33 as a candidate gene for Alzheimer's disease. Mol Psychiatry 2009;14:1004-1016.

19. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC et al: The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:270-279.

20. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr., Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R et al: The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:263-269.

21. Hogervorst E, Xin X, Rahardjo T, Shifu X: The Hopkins Verbal Learning Test and detection of MCI and mild dementia: A literature review. J Alzheimers Dis Parkinsonism 2014;4:2161-0460.1000166.

22. Tsai CL, Liang CS, Lee JT, Su MW, Lin CC, Chu HT, Tsai CK, Lin GY, Lin YK, Yang FC: Associations between Plasma Biomarkers and Cognition in Patients with Alzheimer's Disease and Amnestic Mild Cognitive Impairment: A Cross-Sectional and Longitudinal Study. J Clin Med 2019;8:1893.

23. Ho PS, Yeh YW, Huang SY, Liang CS: A shift toward T helper 2 responses and an increase in modulators of innate immunity in depressed patients treated with escitalopram. Psychoneuroendocrinology 2015;53:246-255.

24. Ho PS, Yen CH, Chen CY, Huang SY, Liang CS: Changes in cytokine and chemokine expression distinguish dysthymic disorder from major depression and healthy controls. Psychiatry Res 2017;248:20-27.

25. Pomeshchik Y, Kidin I, Korhonen P, Savchenko E, Jaronen M, Lehtonen S, Wojciechowski S, Kanninen K, Koistinaho J, Malm T: Interleukin-33 treatment reduces secondary injury and improves functional recovery after contusion spinal cord injury. Brain Behav Immun 2015;44:68-81.

26. Korhonen P, Kanninen KM, Lehtonen S, Lemarchant S, Puttonen KA, Oksanen M, Dhungana H, Loppi S, Pollari E, Wojciechowski S et al: Immunomodulation by interleukin-33 is protective in stroke through modulation of inflammation. Brain Behav Immun 2015;49:322-336.
27. Augustine J, Pavlou S, Ali I, Harkin K, Ozaki E, Campbell M, Stitt AW, Xu H, Chen M: IL-33 deficiency causes persistent inflammation and severe neurodegeneration in retinal detachment. J Neuroinflammation 2019;16:251.

28. Dreis C, Ottenlinger FM, Putyrski M, Ernst A, Huhn M, Schmidt KG, Pfeilschifter JM, Radeke HH: Tissue Cytokine IL-33 Modulates the Cytotoxic CD8 T Lymphocyte Activity During Nutrient Deprivation by Regulation of Lineage-Specific Differentiation Programs. Front Immunol 2019;10:1698.

**Supplementary Figure Legend**

**Supplementary Figure e-1.** Other IL-1 family cytokines were completely expressed.

Abbreviations: aMCI, amnestic mild cognitive impairment; AD, Alzheimer’s disease; HC, healthy controls; IL-1RA, IL-1 receptor antagonist.

**Figures**

![Figure 1](image)

**Figure 1**

Patients with aMCI or AD had higher proportion of peripheral IL-33 expression with linear trend. Pearson’s Chi-Square test: $P = 0.002$; Cochran–Armitage test for linear trend analysis: $P < 0.001$. Abbreviations: aMCI, amnestic mild cognitive impairment; AD, Alzheimer’s disease; HC, healthy controls; IL, interleukin.
Figure 2

Patients with IL-33 expression may preserve cognitive function although having high levels of Aβ1-40. Error bars indicate standard deviation. Abbreviation: Aβ, amyloid β; MMSE, Mini Mental Status Examination, p-Tau, phosphorylated Tau 181; t-Tau, total Tau.

Figure 3

Cognitive preservation was not associated with ApoE4, p-Tau, Aβ1-42, Aβ1-40, and t-Tau, while ApoE ε4 expression and high levels of p-Tau had significantly cognitive decline than their comparators. (a) MMSE change between ApoE4 expression vs ApoE4 non-expression. (b) MMSE change between high levels of p-Tau vs low levels. (c) MMSE change between high levels of Aβ1-42 vs low levels. (d) MMSE change between high levels of Aβ1-40 vs low levels. (e) MMSE change between high levels of t-Tau vs low levels. Error bars indicate standard deviation. Abbreviation: Aβ, amyloid β; MMSE, Mini Mental State Examination; p-Tau, phosphorylated Tau 181; t-Tau, total Tau.

Supplementary Files
This is a list of supplementary files associated with this preprint. Click to download.

- Supplementarydata.pdf